Department of Justice

Mainstream outlets reported that the Justice Department, in an April 23 order signed by Acting Attorney General Todd Blanche, reclassified FDA‑approved marijuana products and state‑licensed medical cannabis from Schedule I to Schedule III — a narrow, medical‑product carve‑out that does not legalize recreational use but aims to ease DEA registration, expand research access, improve banking prospects for state‑licensed firms and allow ordinary federal tax deductions. Coverage traced the regulatory arc (agency reviews, public rulemaking and a December 2025 executive order), noted industry praise and political pushback, and flagged practical effects on research and tax treatment while previewing a June public hearing on broader rescheduling.

What mainstream reporting often omitted were scale and technical details that shape real‑world impact: independent sources show the U.S. medical cannabis market was roughly $7.6 billion in 2025 with some 3.6 million registered patients, and that Section 280E historically blocked ordinary business deductions — producing effective federal tax burdens as high as ~80% for state‑legal sellers. Opinion and analysis pieces amplified perspectives missing from straight news: critics argue the move functions as an industry windfall, may normalize use and harm youth brain development, and shifts benefits toward corporate actors rather than victims or low‑income communities; others warned of symbolic effects and precedent‑setting intervention (e.g., comparisons to a potential Spirit Airlines bailout). Readers would also benefit from more empirical context — longitudinal studies on adolescent cognitive risks, analyses of banking and enforcement outcomes, tax‑revenue modeling under rescheduling, and granular data on patient populations — and from consideration of contrarian views that rescheduling could exacerbate social harms or fail to address underlying equity concerns.